Heather Wakelee, MD

Heather Wakelee, MD, associate professor of medicine, Stanford University Medical Center, discusses unmet needs for immunotherapy in the treatment of patients with non–small cell lung cancer.

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses the current state of treatment in patients with non–small cell lung cancer.

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses dacomitinib in patients with EGFR-positive non–small cell lung cancer.

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses single-agent immunotherapy in patients with non–small cell lung cancer (NSCLC).

Heather Wakelee, MD, associate professor of medicine (oncology) at the Stanford University Medical Center, discussed the latest therapeutic developments in EGFR-mutant non-small cell lung cancer.

Heather Wakelee, MD, associate professor of Medicine (Oncology) at Stanford University Medical Center, discusses available treatment for patients with lung cancer who progress without a T790M mutation.

Heather Wakelee, MD, associate professor of Medicine (Oncology) at Stanford University Medical Center, discusses EGFR tyrosine kinase inhibitors (TKIs) in lung cancer.

Heather Wakelee, MD, professor of medicine, division of oncology, Stanford University, discusses first-line therapy for patients with EGFR-mutant lung cancer.

With several new promising options, Jeffrey Zweig, MD, and Heather Wakelee, MD attempt to better answer the question of which ALK tyrosine kinase inhibitor (TKI) should be favored upfront.

Heather Wakelee, MD, medical oncologist, Stanford University Medical Center, discusses a next-generation sequencing platform for the detection of non-small cell lung cancer (NSCLC) EGFR T790M mutation in urine and plasma samples, during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, discusses how immunotherapy agents compare with targeted therapies in patients with non–small cell lung cancer who harbor genetic alternations.

Heather Wakelee, MD associate professor of Medicine (Oncology) at Stanford University Medical Center, discusses treating EGFR-mutant patients with lung cancer who are resistant to EGFR tyrosine kinase inhibitors (TKIs).

Heather Wakelee, MD, associate professor of medicine, oncology division, Stanford University Medical Center, discusses VeriStrat testing for patients with non-small cell lung cancer.

Heather Wakelee, MD, associate professor, Stanford University School of Medicine, discusses continued maintenance therapy in lung cancer.

Heather Wakelee, MD, an assistant professor at the Stanford University School of Medicine and member of the Stanford Cancer Institute, discusses the results of the AVAPERL trial.

Heather Wakelee, MD, from the Stanford University School of Medicine, describes two phase III trials that focused on the second-line nintedanib plus chemotherapy to treat patients with advanced non-small cell lung cancer.

Dr. Heather Wakelee from the Stanford Clinical Cancer Center on the Future of Lung Cancer Adjuvant Therapy

Dr. Heather Wakelee from Stanford Clinical Cancer Center on Using Lymph Nodes for Lung Cancer Staging

Dr. Heather Wakelee from Stanford Clinical Cancer Center Discusses Adjuvant Therapy Predictive Markers

Dr. Heather Wakelee from Stanford Clinical Cancer Center on Explaining Adjuvant Therapy to Patients

Dr. Heather Wakelee from Stanford Clinical Cancer Center on Adjuvant Therapy in Elderly NSCLC Patients